Stocks of Apellis Pharmaceuticals Inc (APLS) are poised to climb above their peers

With 1.24 million shares changed hands, the volume of the stock remained lighter than its average volume of 1.57 million shares. The 52-week range on APLS shows that it touched its highest point at $94.75 and its lowest point at $19.83 during that stretch. It currently has a 1-year price target of $82.69. Beta for the stock currently stands at 0.88.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of APLS was up-trending over the past week, with a rise of 3.83%, but this was down by -8.23% over a month. Three-month performance dropped to -6.61% while six-month performance rose 51.36%. The stock lost -9.54% in the past year, while it has lost -1.80% so far this year. A look at the trailing 12-month EPS for APLS yields -4.48 with Next year EPS estimates of 1.43. For the next quarter, that number is -0.47. This implies an EPS growth rate of 78.33% for this year and 248.60% for next year. EPS is expected to grow by 33.30% annually over the next five years; however, over the past five years, the company experienced an annual growth rate of -13.70%.

Float and Shares Shorts:

At present, 119.56 million APLS shares are outstanding with a float of 98.84 million shares on hand for trading. On Mar 15, 2024, short shares totaled 10.59 million, which was 8.78% higher than short shares on Feb 15, 2024. In addition to Dr. Cedric Francois M.D., Ph.D. as the firm’s Co-Founder, President, CEO & Director, Dr. Pascal Deschatelets Ph.D. serves as its Co-Founder & Chief Scientific Officer.

Institutional Ownership:

Through their ownership of 96.00% of APLS’s outstanding shares, institutional investors have majority control over the company.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for APLS since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.

Dividends & Yield:

In terms of dividends, APLS has a current ratio of $––, which is $–– over the trailing 12-months, while a dividend of $–– is likely to be paid on average over the next five years. Dividend yield is another indicator that appeals to many investors, and APLS currently yields $0.00. In the past year, APLS’s dividend yield has been $0.00, but when looking at the stock over the past five years, its yield has been $–. Accordingly, APLS has a current buyback yield of $–. This was $– for the TTM, and it was $– for the past five years.